Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Tharimmune Inc
THAR
Healthcare
Biotechnology
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active...
compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:THAR)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 28, 2024 9:26am
THAR....News released
On watch Could be the steal of the Century
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 28, 2024 9:10am
New Press Release - Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profileTH104 was well tolerated with no unexpected treatment-emergent adverse events, supporting further clinical developmentCompany expects Phase...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 25, 2024 8:01am
New Press Release - Tharimmune Announces Upcoming Conference Presentations
BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 07, 2024 1:40pm
THAR....I stand corrected on my last post
Mr. M has been listening to me....and he decided to abandon his support and just manip it down on low volume Keep up the good work kind Sir ; )
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Oct 07, 2024 12:41pm
RE:THAR....all-time low at $2
Here is the NR from last July.... Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor 2024-07-10 05:32 ET - News Release BRIDGEWATER, NJ / ACCESSWIRE / July 10,
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 07, 2024 11:56am
THAR....all-time low at $2
with a "Billionaire" at the helm Whats not to like ; )
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 30, 2024 7:23am
New Press Release - Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
- Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - Merger anticipated to close in 1Q25BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 25, 2024 1:48pm
THAR....I always say ; )
Big bids sink ships The Sun Tzu art of war .....LoL
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 25, 2024 1:45pm
THAR.... Big bids keep getting posted but nothing
happens....all small lots driving the price down. Is that you Mr. M???? Fess up
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 25, 2024 1:34pm
THAR....at this rate....sub $2 anyone ??
Cheers !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 25, 2024 1:17pm
THAR.....New all-time low.....$2.3227
manipped exclusively by noe other than ..... Mr. M ; )
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 25, 2024 1:11pm
THAR.....last at $2.34 ; )
Keep er going Buddy Cheers !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 25, 2024 1:08pm
THAR.....I guees Mr, M is reading my posts ...LoL
Down on low volume.......This will be a huge win.....Right Mr. M???? Come on ....whack the bid harder !!!!!!!
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Sep 25, 2024 12:47pm
RE:THAR.....New All-time low just crossed the tape
Ur doin a heck of a job Mr. M......new all time low now $2.46....keep it heading South Buddy ; )
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 25, 2024 12:27pm
THAR.....New All-time low just crossed the tape
$2.515 Cheap paper makes the world go around....right?
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities